Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Qualigen Therapeutics, Inc. (RTTR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/16/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
| 05/01/2020 |
8-K
| Quarterly results |
| 03/31/2020 |
8-K
| Quarterly results |
| 02/27/2017 |
8-K
| Form 8-K - Current report |
| 11/07/2016 |
8-K
| Quarterly results|
Docs:
|
"RITTER PHARMACEUTICALS, INC. CONDENSED STATEMENTS OF OPERATIONS Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Operating costs and expenses: Research and development $ 2,348,755 $ 1,505,116 $ 7,112,177 $ 1,584,086 Patent costs 98,908 47,611 199,888 160,033 General and administrative 1,091,647 1,555,938 3,533,608 4,860,676 Total operating costs and expenses 3,539,310 3,108,665 10,845,673 6,604,795 Operating loss Other income: Interest income 13,239 18,853 50,466 23,157 Other income — 9,590 1,214 16,682 Total other income 13,239 28,443 51,680 39,839 Net loss $ $ $ $ Cumulative preferred stock dividends — — — Accretion of discount on Series C preferred stock — — — Net loss applicable to common shareholders $ $ $ $ Net loss per common share ? basic and d..." |
|
|
|